1 Mortality at maximal follow‐up |
6 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
1.1 Colchicine vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
1.2 Penicillamine vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
1.3 Steroids vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
1.4 Ursodeoxycholic acid (high) vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
1.5 Ursodeoxycholic acid (moderate) vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
1.6 Vancomycin vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
2 Serious adverse events proportion |
3 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
2.1 Infliximab vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
2.2 Steroids vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
2.3 Vancomycin vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
3 Serious adverse events number |
4 |
|
rate ratio (Fixed, 95% CI) |
Totals not selected |
3.1 Infliximab vs placebo |
1 |
|
rate ratio (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
3.2 Penicillamine vs placebo |
1 |
|
rate ratio (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
3.3 Steroids vs placebo |
1 |
|
rate ratio (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
3.4 Ursodeoxycholic acid (high) vs ursodeoxycholic acid (moderate) |
1 |
|
rate ratio (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
3.5 Ursodeoxycholic acid (high) vs ursodeoxycholic acid (low) |
1 |
|
rate ratio (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
3.6 Ursodeoxycholic acid (moderate) vs ursodeoxycholic acid (low) |
1 |
|
rate ratio (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
4 Adverse events proportion |
3 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
4.1 Steroids vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
4.2 Ursodeoxycholic acid (moderate) vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
4.3 Vancomycin vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
5 Adverse events number |
6 |
|
rate ratio (Fixed, 95% CI) |
Totals not selected |
5.1 Cyclosporin vs placebo |
1 |
|
rate ratio (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
5.2 Penicillamine vs placebo |
1 |
|
rate ratio (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
5.3 Steroids vs placebo |
1 |
|
rate ratio (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
5.4 Ursodeoxycholic acid (high) vs ursodeoxycholic acid (low) |
1 |
|
rate ratio (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
5.5 Ursodeoxycholic acid (high) vs ursodeoxycholic acid (moderate) |
1 |
|
rate ratio (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
5.6 Ursodeoxycholic acid (low) plus metronidazole vs ursodeoxycholic acid (low) |
1 |
|
rate ratio (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
5.7 Ursodeoxycholic acid (moderate) vs ursodeoxycholic acid (low) |
1 |
|
rate ratio (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
5.8 Vancomycin vs metronidazole |
1 |
|
rate ratio (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
6 Quality of life |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
6.1 Ursodeoxycholic acid (moderate) vs placebo |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
7 Liver transplantation |
8 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
7.1 Colchicine vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
7.2 Penicillamine vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
7.3 Steroids vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
7.4 Ursodeoxycholic acid (high) vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
7.5 Ursodeoxycholic acid (moderate) vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
7.6 Vancomycin vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
7.7 Ursodeoxycholic acid (moderate) vs ursodeoxycholic acid (low) |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
7.8 Ursodeoxycholic acid (high) vs ursodeoxycholic acid (low) |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
7.9 Ursodeoxycholic acid (high) vs ursodeoxycholic acid (moderate) |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
7.10 Ursodeoxycholic acid (low) plus metronidazole vs ursodeoxycholic acid (low) |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
8 Cholangiocarcinoma |
4 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
8.1 Cyclosporin vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
8.2 Ursodeoxycholic acid (high) vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
8.3 Ursodeoxycholic acid (moderate) vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
8.4 Vancomycin vs placebo |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |